Anti-inflammatory cytokine response and the development of multiple organ failure in severe sepsis

Acta Anaesthesiologica Scandinavica

Volumn 47, Issue 3, 2003, Pages 319-325

  Loisa, Pekka ^a,c   Rinne, T ^a   Laine, S ^a   Hurme, M ^b   Kaukinen, S ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c Central Hospital   (Finland)

Author keywords

Interleukin 10; Interleukin 6; Multiple organ failure; Sepsis

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS;

ADULT; BLOOD PRESSURE; CARDIAC OUTPUT; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; OXYGEN; PROSPECTIVE STUDIES; SEPSIS; VASCULAR RESISTANCE;

EID: 0037353346     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-6576.2003.00004.x     Document Type: Article

References (33)

1. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997; 66: 101-95.
2. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1: 355-7.
3. Martin C, Saux P, Mege J-L, Perrin G, Papazian L, Gouin F. Prognostic value of serum cytokines in septic shock. Intensive Care Med 1994; 20: 272-7.
4. Goldie AS, Fearon KC, Ross JA et al. Natural cytokine antagonist and endogenous antiendotoxin core antibodies in sepsis syndrome. The sepsis intervention group. JAMA 1995; 274: 172-7.
5. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103: 565-75.
6. Damas P, Ledoux D, Nys M et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215: 356-62.
7. Casey LC, Balk RA, Bone RC, Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Intern Med 1993; 119: 771-8.
8. Hack CE, Degroot ER, Felt-Bersma RJF et al. Increased plasma level of interleukin-6 in sepsis. Blood 1989; 74: 1704-10.
9. Calandra T, Gerain J, Heuman D, Baumgartner J-D, Glauser MP. High circulating levels of IL-6 in patients with septic shock. Evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1991; 91: 23-9.
10. Granowitz EV, Santos AA, Poutsiaka DD et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 1991; 338: 1423-24.
11. Marchant A, Deviere J, Byl B, De Groote D, Vincent J-L, Goldman M. Interleukin-10 production during septicemia. Lancet 1994; 343: 707-8.
12. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-52.
13. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815-22.
14. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Ann Rev Immunol 1993; 11: 165-90.
15. Marchant A, Bruyns C, Vandenabeele P et al. Interleukin-10 controls interferon-γ and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994; 24: 1167-71.
16. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996; 125: 680-7.
17. Opal SM, Fisher CJ, Dhainaut J-FA et al. Confirmatory interleukin-1 antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25: 1115-23.
18. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997; 112: 321S-329S.
19. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S. High levels of interleukin-10 during the initial phase of fulminant menigococcal septic shock. J Infect Dis 1995; 171: 229-32.
20. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000; 181: 176-80.
21. Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 1999; 27: 1262-64.
22. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
23. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-8.
24. Vincent JL, Moreno R, Takala J et al. The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22: 707-10.
25. Vincent J-L, de Medonca A, Cantraine F et al. Use of SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Crit Care Med 1998; 26: 1793-1800.
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Apache II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
27. Nijsten MW, de Groot ER, ten Duis HJ, Klasen HJ, Hack CE, Aarden LA. Serum levels of interleukin-6 and acute phase responses. Lancet 1987; 2: 921.
28. Howard BM, Muchamuel T, Andrade S, Menon S. Interleukin-10 protects mice from lethal endotoxemia. J Exp Med 1993; 177: 1205-8.
29. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL. Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995; 155: 2222-9.
30. Van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frölich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998; 351: 950-3.
31. Donnelly SC, Strieter RM, Reid PT et al. The association between mortality rates and decreased concentrations in the lung fluids of patients with the adult respiratory distress syndrome. Ann Int Med 1996; 125: 191-6.
32. Armstrong L, Millar AB. Relative production of tumour necrosis factor and interleukin-10 in adult respiratory distress syndrome. Thorax 1997; 52: 442-6.
33. Simovic MO, Bonham JD, Abu-Zidan FM, Windsor JA. Anti-inflammatory cytokine response and clinical outcome in acute pancreatitis. Crit Care Med 1999; 27: 2662-5.